Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Fortress Biotech Inc. (FBIO:NASDAQ), powered by AI.
Fortress Biotech Inc. is currently trading at $2.93. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Fortress Biotech Inc. on Alpha Lenz.
Fortress Biotech Inc.'s P/E ratio is 12.0.
“Fortress Biotech Inc. trades at a P/E of 12.0 (undervalued) with strong ROE of 18.8%.”
Ask for details →Fortress Biotech Inc. operates as a biopharmaceutical company involved in the development and commercialization of novel pharmaceutical and biotechnology products. Its primary function is to nurture and advance a diverse portfolio of potential new treatments for rare diseases, cancer, and other serious health conditions. A distinctive feature of Fortress Biotech is its innovative partnership model; it acquires, develops, and commercializes these therapies through multiple subsidiary companies and licensing agreements. This structure allows for specialized focus and flexibility in progressing early-stage drug candidates. Fortress Biotech significantly impacts the healthcare sector, particularly in areas of unmet medical needs where it seeks to bring breakthrough therapies to market. By creating a platform for research and development across its subsidiaries, the company plays a crucial role in fostering advancements in medical treatments and addressing critical gaps within pharmaceutical innovation and patient care.
“Fortress Biotech Inc. trades at a P/E of 12.0 (undervalued) with strong ROE of 18.8%.”
Ask for details →Fortress Biotech Inc. (ticker: FBIO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 101 employees. Market cap is $82M.
The current price is $2.93 with a P/E ratio of 12x and P/B of 1.64x.
ROE is 18.77% and operating margin is -111.00%. Annual revenue is $63M.